Table 2. Summary of the immune-related adverse events and drug exposure in the durvalumab and atezolizumab groups.

All-cause IRAEs, treatment-related AEs and AESIs	Durvalumab group (N=100)				Atezolizumab group (N=43)
	Any grade	≥3 grade	P		Any grade	≥3 grade	P
Any IRAE, n (%)	23 (23.0)	10 (10.0)	0.37		7 (16.3)	1 (2.3)	0.22
Im pneumonitis, n (%)	6 (6.0)	2 (2.0)	0.61		1 (2.3)	0	1.00
Im chest distress, n (%)	1 (1.0)	0	1.00		0	0	1.00
Im diseases of endocrine system, n (%)	3 (3.0)	2 (2.0)	0.53		3 (7.0)	0	0.16
Im hepatitis, n (%)	5 (5.0)	4 (4.0)	0.31		0	0	0.52
Im rash, n (%)	4 (4.0)	1 (1.0)	1.00		2 (4.7)	0	1.00
Im esophagitis, n (%)	1 (1.0)	0	1.00		0	0	0.22
Im peritonitis, n (%)	1 (1.0)	0	1.00		0	0	0.22
Im enteritis, n (%)	2 (2.0)	0	1.00		1 (2.3)	0	1.00
Im toxicity, n (%)	2 (2.0)	0	1.00		0	0	1.00
Im damage, n (%)	2 (2.0)	0	1.00		1 (2.3)	1 (2.3)	0.36
Im cardiotoxicity, n (%)	4 (4.0)	2 (2.0)	0.36		0	0	1.00
Im fatigue, n (%)	2 (2.0)	1 (1.0)	1.00		0	0	1.00
Number of patients with IRAEs, n (%)	23 (23.0)	11 (11.0)			7 (16.3)	1 (2.3)	0.37
Number of doses received, median [range]	6.0 [1–23]				5.0 [1–31]		0.91
Treated with steroids therapy, n (%)	11 (47.8)				0		0.06
Any permanent cessation due to IRAEs, n (%)	10 (10.0)				2 (4.7)		0.79
Any IRAE leading to death	0				0		1

IRAE, immune-related adverse event; AE, adverse event; Im, immune-mediated; AESI, adverse event of special interest.